ECSP099178A - Método de tratamiento del ictus con un trombolítico - Google Patents

Método de tratamiento del ictus con un trombolítico

Info

Publication number
ECSP099178A
ECSP099178A EC2009009178A ECSP099178A ECSP099178A EC SP099178 A ECSP099178 A EC SP099178A EC 2009009178 A EC2009009178 A EC 2009009178A EC SP099178 A ECSP099178 A EC SP099178A EC SP099178 A ECSP099178 A EC SP099178A
Authority
EC
Ecuador
Prior art keywords
treatment
administration
thrombolitic
ictus
embolate
Prior art date
Application number
EC2009009178A
Other languages
English (en)
Inventor
Peter Kuebler
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099178(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ECSP099178A publication Critical patent/ECSP099178A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un método para el tratamiento del ictus isquémico agudo en humanos comprende la administración de tenecteplasa al humano en una dosis total de 0,05 a 0,5 mg/kg aproximadamente (a) mediante administración en embolada de una dosis inicial comprendida entre alrededor de 0,05 y 0,15 mg/kg, seguida de infusión de una cantidad igual a la dosis total menos la dosis inicial durante un periodo de 50 a 90 minutos aproximadamente, o (b) mediante administración en embolada. También se describen los kits para aplicar este método.
EC2009009178A 2006-08-29 2009-03-12 Método de tratamiento del ictus con un trombolítico ECSP099178A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29

Publications (1)

Publication Number Publication Date
ECSP099178A true ECSP099178A (es) 2009-06-30

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009178A ECSP099178A (es) 2006-08-29 2009-03-12 Método de tratamiento del ictus con un trombolítico

Country Status (21)

Country Link
US (2) US20080107641A1 (es)
EP (1) EP2056856B1 (es)
JP (1) JP5785687B2 (es)
KR (1) KR20090045405A (es)
CN (1) CN101505785A (es)
AU (1) AU2007290277B2 (es)
BR (1) BRPI0716143A2 (es)
CA (1) CA2661012C (es)
CO (1) CO6150188A2 (es)
EA (1) EA015573B1 (es)
EC (1) ECSP099178A (es)
IL (2) IL196987A (es)
MX (1) MX2009001918A (es)
MY (1) MY163119A (es)
NO (1) NO342302B1 (es)
NZ (1) NZ574767A (es)
SG (3) SG10201501498VA (es)
TW (1) TWI439282B (es)
UA (1) UA97486C2 (es)
WO (1) WO2008027687A2 (es)
ZA (1) ZA200900957B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
KR101315904B1 (ko) 2005-02-24 2013-10-08 디퓨젼 파마슈티컬즈 엘엘씨 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도
CN101505785A (zh) 2006-08-29 2009-08-12 健泰科生物技术公司 替奈普酶用于治疗急性缺血性中风的用途
EP2589588A1 (en) 2007-04-13 2013-05-08 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
RU2011130888A (ru) * 2008-12-24 2013-01-27 Конинклейке Филипс Электроникс Н.В. Система, способ и устройство для вмешательства на сердце с магнитно-резонансной (mr) диагностикой инсульта и его лечением
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
AU2010289838C1 (en) * 2009-08-24 2014-03-06 Hough Ear Institute Methods for treating acute acoustic trauma
CN103124498A (zh) 2010-06-02 2013-05-29 扩散药品有限公司 双极性反式类胡萝卜素的口服制剂
AU2011346515B2 (en) 2010-12-23 2017-01-19 Gennova Biopharmaceuticals Ltd. Pharmaceutical compositions of tenecteplase
US20150238502A1 (en) 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
US8690907B1 (en) 2013-03-15 2014-04-08 Insera Therapeutics, Inc. Vascular treatment methods
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
JP6437517B2 (ja) 2013-03-15 2018-12-12 インセラ セラピューティクス，インク． 血管治療装置及び方法
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
DK3209767T3 (da) * 2014-10-21 2020-11-02 Gennova Biopharmaceuticals Ltd Hidtil ukendt oprensningsfremgangsmåde til isolering og kommerciel fremstilling af rekombinant tnk-tpa (tenecteplase)
CN108697423A (zh) 2016-02-16 2018-10-23 伊瑟拉医疗公司 抽吸装置和锚定的分流装置
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER
CN110214015A (zh) * 2017-01-24 2019-09-06 Ekos公司 用于治疗血栓栓塞的方法
WO2018210860A1 (en) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2021158799A1 (en) * 2020-02-04 2021-08-12 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2
IL295727A (en) * 2020-02-19 2022-10-01 Nono Inc Combined treatment of stroke with a plasmin-degradable and reperfusion psd-95 inhibitor
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69333127T2 (de) 1992-06-03 2004-05-06 Genentech, Inc., South San Francisco Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
CN101505785A (zh) 2006-08-29 2009-08-12 健泰科生物技术公司 替奈普酶用于治疗急性缺血性中风的用途

Also Published As

Publication number Publication date
JP5785687B2 (ja) 2015-09-30
IL248176A0 (en) 2016-11-30
CO6150188A2 (es) 2010-04-20
SG10201501498VA (en) 2015-04-29
EA015573B1 (ru) 2011-10-31
MY163119A (en) 2017-08-15
AU2007290277B2 (en) 2013-04-11
NZ574767A (en) 2012-02-24
TWI439282B (zh) 2014-06-01
CA2661012C (en) 2019-03-19
EP2056856A2 (en) 2009-05-13
WO2008027687A3 (en) 2008-05-22
EA200970237A1 (ru) 2009-08-28
IL196987A (en) 2016-10-31
NO342302B1 (no) 2018-04-30
AU2007290277A1 (en) 2008-03-06
US20120164157A1 (en) 2012-06-28
TW200817033A (en) 2008-04-16
WO2008027687A2 (en) 2008-03-06
ZA200900957B (en) 2010-05-26
IL196987A0 (en) 2011-08-01
UA97486C2 (ru) 2012-02-27
US9023346B2 (en) 2015-05-05
JP2010502629A (ja) 2010-01-28
EP2056856B1 (en) 2015-01-14
CN101505785A (zh) 2009-08-12
SG174753A1 (en) 2011-10-28
NO20091296L (no) 2009-05-28
KR20090045405A (ko) 2009-05-07
US20080107641A1 (en) 2008-05-08
HK1131054A1 (en) 2010-01-15
SG10201804944XA (en) 2018-07-30
CA2661012A1 (en) 2008-03-06
MX2009001918A (es) 2009-03-06
BRPI0716143A2 (pt) 2013-11-26

Similar Documents

Publication Publication Date Title
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
AR112015A1 (es) Composiciones sólidas para administración oral
MX2018009173A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2009005798A (es) Recuperacion de apoplejia.
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
RU2007122391A (ru) S-миртазапин для лечения приливов
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
MX2022001647A (es) Terapia de combinacion con vildagliptina y metformina.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR057155A1 (es) Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina
AR063530A1 (es) Procedimiento de utilizacion de enoxaparina sodica para la preparacion de un medicamento